Literature DB >> 6265942

Adenosine receptors and behavioral actions of methylxanthines.

S H Snyder, J J Katims, Z Annau, R F Bruns, J W Daly.   

Abstract

Central stimulant actions of 10 methylxanthines in mice correlate with affinities for adenosine receptors labeled with N6-[3H]cyclohexyladenosine. Affinities of methylxanthines for adenosine receptors are consonant with central levels attained at behaviorally effective doses. The much higher concentrations of methylxanthines required to influence benzodiazepine receptor binding do not correlate with behavioral potency. N6-(L-Phenylisopropyl)adenosine (L-PIA), a metabolically stable analog of adenosine with high affinity for adenosine receptors, is an extremely potent behavioral depressant, reducing locomotor activity of mice at doses as little as 0.05 mumol/kg. The D isomer, which has much less affinity for adenosine receptors, is much less active as a central depressant. Theophylline stimulates locomotor activity and reverses depressant effects of L-PIA. Caffeine or 1,7-dimethylxanthine, when administered alone, elicits biphasic effects, with locomotor depression at lower doses and stimulation at higher doses. When administered with L-PIA, even low doses of caffeine produce marked stimulation. 3-Isobutyl-1-methylxanthine given alone elicits only behavioral depression. However, like theophylline and caffeine, isobutylmethylxanthine reverses the L-PIA-evoked depression, converting it into pronounced locomotor stimulation. The data strongly suggest that the behavioral stimulant effects of methylxanthines involve a blockade of central adenosine receptors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265942      PMCID: PMC319541          DOI: 10.1073/pnas.78.5.3260

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

2.  Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity.

Authors:  F W Smellie; C W Davis; J W Daly; J N Wells
Journal:  Life Sci       Date:  1979-06-25       Impact factor: 5.037

3.  The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices.

Authors:  A Sattin; T W Rall
Journal:  Mol Pharmacol       Date:  1970-01       Impact factor: 4.436

4.  Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase activity.

Authors:  J A Beavo; N L Rogers; O B Crofford; J G Hardman; E W Sutherland; E V Newman
Journal:  Mol Pharmacol       Date:  1970-11       Impact factor: 4.436

5.  Cyclic adenosine monophosphate phosphodiesterase in brain: effect on anxiety.

Authors:  B Beer; M Chasin; D E Clody; J R Vogel
Journal:  Science       Date:  1972-04-28       Impact factor: 47.728

6.  Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations.

Authors:  A Thithapandha; H M Maling; J R Gillette
Journal:  Proc Soc Exp Biol Med       Date:  1972-02

7.  Saturable binding of adenosine to the dog heart microsomal fraction: competitive inhibition by aminophylline.

Authors:  P Dutta; S J Mustafa
Journal:  J Pharmacol Exp Ther       Date:  1979-12       Impact factor: 4.030

8.  Characterization of [3H]adenosine binding to fat cell membranes.

Authors:  C C Malbon; R C Hert; J N Fain
Journal:  J Biol Chem       Date:  1978-05-10       Impact factor: 5.157

9.  Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA).

Authors:  H Vapaatalo; D Onken; P J Neuvonen; E Westermann
Journal:  Arzneimittelforschung       Date:  1975-03

10.  Effect of some phosphodiesterase inhibitors on central dopamine mechanisms.

Authors:  B B Fredholm; K Fuxe; L Agnati
Journal:  Eur J Pharmacol       Date:  1976-07       Impact factor: 4.432

View more
  131 in total

1.  Possible mechanism of interaction of GABAergic-adenosinergic systems in the regulation of theophylline-induced locomotor activity under its nontolerant and tolerant conditions.

Authors:  M Mandal; M K Poddar
Journal:  Neurochem Res       Date:  1999-06       Impact factor: 3.996

2.  Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor.

Authors:  J W Daly; J Caceres; R W Moni; F Gusovsky; M Moos; K B Seamon; K Milton; C W Myers
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

3.  Late ontogenetic development of adenosine A1 receptor coupling to associated G-proteins in guinea pig cerebellum but not forebrain.

Authors:  P F Morgan; J Deckert; T Nakajima; J L Daval; P J Marangos
Journal:  Mol Cell Biochem       Date:  1990-02-09       Impact factor: 3.396

4.  Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX.

Authors:  G Griebel; M Saffroy-Spittler; R Misslin; D Remmy; E Vogel; J J Bourguignon
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors.

Authors:  Katerina Antoniou; Zeta Papadopoulou-Daifoti; Thomas Hyphantis; Georgia Papathanasiou; Efstathios Bekris; Marios Marselos; Leigh Panlilio; Christa E Müller; Steven R Goldberg; Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

6.  Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling.

Authors:  Bogachan Sahin; Stacey Galdi; Joseph Hendrick; Robert W Greene; Gretchen L Snyder; James A Bibb
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

Review 7.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 8.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 9.  Exploring cocoa properties: is theobromine a cognitive modulator?

Authors:  Ilaria Cova; V Leta; C Mariani; L Pantoni; S Pomati
Journal:  Psychopharmacology (Berl)       Date:  2019-01-31       Impact factor: 4.530

10.  Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations.

Authors:  H Ratech; M A Greco; G Gallo; D L Rimoin; H Kamino; R Hirschhorn
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.